Privium Fund Management (Uk) LTD Graphite Bio, Inc. Transaction History

Privium Fund Management (Uk) LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$2.18 - $2.77 $156,118 - $198,370	-71,614 Reduced 27.24%	191,244 $474,000
Q2 2023 Jul 25, 2023	SELL	$2.47 - $3.38 $46,690 - $63,892	-18,903 Reduced 6.71%	262,858 $683,000
Q1 2023 May 03, 2023	SELL	$1.85 - $3.21 $611,876 - $1.06 Million	-330,744 Reduced 54.0%	281,761 $690,000
Q4 2022 Feb 09, 2023	BUY	$2.82 - $3.59 $134,116 - $170,736	47,559 Added 8.42%	612,505 $2.03 Million
Q3 2022 Nov 01, 2022	BUY	$2.82 - $4.24 $621,468 - $934,406	220,379 Added 63.96%	564,946 $1.79 Million
Q2 2022 Jul 28, 2022	BUY	$2.14 - $5.23 $737,373 - $1.8 Million	344,567 New	344,567 $948,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Privium Fund Management (Uk) LTD, based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management (Uk) LTD with notifications on news.